How to Select Target Categories for Health Supplements in China: 2026 Guide

China’s health supplement market is projected to reach 300 billion RMB by 2026, yet foreign brands face a critical bottleneck: choosing the right functional category among 27 registered Blue Hat categories (蓝帽子, lán màozi). The registration framework provides a data-driven framework for selecting target categories for 保健食品 (health supplements, bǎojiàn shípǐn) registration under the 国家市场监督管理总局 (State Administration for Market Regulation, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú, SAMR), based on 2026 regulatory trends, market demand, and clinical evidence requirements.

Why Category Selection Determines Market Success in 2026

The 2026 regulatory environment under SAMR is tightening claim validation. In 2025, SAMR rejected 34% of new health supplement applications due to insufficient evidence for functional claims — up from 22% in 2022. Each rejected application costs foreign brands an average of 1.2–1.8 million RMB in wasted testing, translation, and legal fees. The right category choice directly determines approval probability, time-to-market, and competitive positioning.

China currently recognizes 27 registered functional categories for health supplements, plus a separate nutrient supplement pathway for vitamins and minerals. However, only 8 categories accounted for 76% of all approved products between 2022 and 2025: immune support, digestive health, blood lipid management, bone health, antioxidant, sleep improvement, weight management, and liver protection.

Foreign brands must also navigate the 保健食品注册与备案管理办法 (Health Food Registration and Filing Administration Measures, bǎojiàn shípǐn zhùcè yǔ bèi’àn guǎnlǐ bànfǎ), which introduces stricter clinical trial requirements for certain high-risk categories starting January 2026. Categories flagged for elevated scrutiny include weight management, blood glucose control, and blood pressure regulation — precisely the categories with the highest consumer demand growth.

2026 Market Trends Reshaping Category Priorities

Demographic Shifts Driving New Demand

China’s aging population — 310 million citizens aged 60+ by 2026 — is reshaping supplement demand. Bone health (骨骼健康, gǔgé jiànkāng), cardiovascular support (心血管健康, xīnxuèguǎn jiànkāng), and cognitive function (认知功能, rènzhī gōngnéng) are the fastest-growing categories among seniors, with compound annual growth rates (CAGR) of 14%, 12%, and 11% respectively from 2023 to 2026.

Simultaneously, post-pandemic health awareness has created lasting demand for immune support (免疫健康, miǎnyì jiànkāng). In 2025, immune-related supplements represented 23% of all health supplement sales in China, up from 15% in 2020. However, SAMR has responded by raising the clinical evidence bar for immune claims, requiring randomized controlled trials (RCTs) with at least 200 participants per claim.

E-Commerce Channel Dynamics

Cross-border e-commerce (跨境电商, kuàjìng diànshāng) platforms like Tmall Global and JD Worldwide now account for 42% of health supplement sales to Chinese consumers. These channels are less restrictive on category registration — products can be sold as general foods with health claims under certain conditions — but the 2026 跨境电商零售进口商品清单 (Cross-border E-commerce Retail Import Commodity List, kuàjìng diànshāng língshòu jìnkǒu shāngpǐn qīngdān) has removed 12 supplement categories from the permitted list, including melatonin and certain enzyme products.

For foreign brands, this means category selection is not just a regulatory decision — it is a channel strategy decision. Categories that are permitted under cross-border e-commerce can be brought to market in 3–6 months, while full Blue Hat registration through the domestic channel takes 12–24 months.

A Step-by-Step Framework for Category Selection

Step 1: Assess Clinical Evidence Readiness

Before targeting any category, audit your existing clinical data against SAMR’s 保健食品功能评价方法 (Health Food Functional Evaluation Methods, bǎojiàn shípǐn gōngnéng píngjià fāngfǎ). Each of the 27 categories has specific testing protocols. For example, bone health claims require animal bone density studies plus human trials showing calcium absorption improvement. Sleep improvement claims require polysomnography or validated sleep questionnaires.

Foreign brands typically spend 2–5 million RMB conducting China-specific clinical trials for a single category claim. Brands without existing China-compliant data should prioritize categories with lower evidence thresholds, such as nutrient supplements (备案制, bèi’àn zhì, filing system) which require only composition and safety data rather than functional efficacy trials.

Step 2: Map Market Demand to Regulatory Feasibility

The following table compares the top 10 health supplement categories by market demand, approval rate, and estimated time-to-market for foreign brands:

Source: SAMR 2025 Annual Report on Health Food Registration; China Health Food Association Market Data 2025. Approval rates are for first-time applications by foreign brands.

Step 3: Evaluate Channel Compatibility

Nutrient supplements (备案制 products) can be sold through both domestic and cross-border e-commerce channels with minimal additional registration. Functional health supplements (注册制, zhùcè zhì, registration system) require full Blue Hat certification for the domestic channel but may be sold as general food with limited claims through cross-border platforms — provided the category appears on the permitted import list.

The 2026 跨境电商零售进口商品清单 now permits 58 supplement categories for cross-border sale, but excludes high-risk categories such as weight management products containing stimulants, liver protection products containing botanical extracts with known hepatotoxicity, and cognitive function products claiming Alzheimer’s prevention. Brands targeting these excluded categories must pursue full domestic registration.

Decision Framework: Matching Your Product to the Right Category

Use the following decision framework to narrow your category options:

If your product has robust RCT data from an FDA or EMA-compliant trial — choose a high-demand functional category like immune support or blood lipid management. The existing data can be adapted for SAMR submission with supplemental China-specific studies, reducing overall cost by 30–50% compared to starting from scratch.

If your product has only in vitro or animal data — choose digestive health or antioxidant categories. These require the least human clinical evidence among functional categories, with SAMR accepting biomarker studies and microbiome analysis in place of full RCTs.

If your product is a single nutrient or vitamin/mineral combination — choose the nutrient supplement (备案制) pathway. This is the fastest and most cost-effective route, with approval rates above 90% and time-to-market under 12 months. However, you cannot make functional claims beyond “supplements daily nutritional needs.”

If your product contains traditional Chinese medicine (TCM) ingredients — choose a category with an established TCM precedent, such as liver protection (using Schisandra or milk thistle) or sleep improvement (using Ziziphus or GABA). SAMR has a dedicated evaluation pathway for TCM-derived health supplements with slightly lower evidence thresholds for well-documented botanicals.

If your product’s primary ingredient is novel or unfamiliar to Chinese regulators — choose a lower-risk functional category like antioxidant or bone health, and invest in ingredient safety dossier preparation. Novel ingredients face a 12–18 month safety review before functional testing can begin.

3 Pitfalls to Avoid in Category Selection

2026 Outlook: Categories to Watch

Based on regulatory signals from SAMR and consumer trends, three categories are positioned for accelerated growth in 2026 and 2027:

Probiotics and digestive health — SAMR is expected to streamline the approval process for probiotic-based health supplements, reducing clinical trial requirements from 12 months to 6 months for well-documented strains. The Chinese probiotic market is projected to reach 80 billion RMB by 2027, with digestive health supplements accounting for 35% of that total.

Bone health with vitamin K2 and collagen peptides — The aging population combined with rising awareness of osteoporosis has made bone health the second-fastest-growing category. SAMR has issued draft guidelines for accepting international bone density data, potentially reducing China-specific trial costs by 40%.

Cognitive function focusing on mild cognitive impairment (MCI) — While full Alzheimer’s claims are prohibited, SAMR is developing a new sub-category for MCI support, expected to finalize by mid-2027. Early-mover foreign brands that begin R&D now will be positioned for first-to-market advantage.

NEXT STEPS

Based on this analysis, here are three concrete actions to advance your category selection:

1. Audit your existing clinical evidence against SAMR’s 27 functional category requirements. Use the evaluation methods published under 保健食品功能评价方法 to identify gaps. For a detailed breakdown of each category’s testing protocols, see our China Health Supplement Registration Guide.
2. Commission a China-specific market perception survey for your top three candidate categories. Consumer awareness and preference vary significantly by region and age group. Our Market Research for Health Supplements in China article explains how to design and execute a compliant survey.
3. Begin ingredient sourcing documentation with a CNAS-accredited Chinese testing lab early. Ingredient dossiers take 3–6 months to prepare and are the leading cause of application delays. Read our Ingredient Sourcing Compliance Checklist for step-by-step guidance.

— China Gateway 360 —
Remote China market entry support, built around execution.

Official Sources

• National Bureau of Statistics of China
• Ministry of Commerce: Foreign Investment Guide
• National Development and Reform Commission